Conversation 165: MedAdvisor
Britain and America’s poor state of health may benefit Medavisor’s push to be a global player.
There is no shortage of free apps to help you connect with your pharmacy to order your latest medication, or for that matter, to remind you to take it.
But the CEO of Medadvisor, which is just such an app, says they are different.
Here are some of the reasons he believes this is so:
App use leads to around 20% improved compliance of taking and following medication recommended by health professional.
Better compliance leads to increased revenue for both the drug company and the dispensing pharmacist.
Drug companies pay Medadvisor per app user and provide significant content that Medadvisor algorithms use to drip feed valuable information to patients at appropriate times.
Two USA deals will see a different revenue model where MedAdvisor gets paid per message sent to a patient and one of its new American partners sent out 865 million messages last year.
According to Robert Read, CEO of Medadvisor, the app, either directly, or as a white label, which allows companies like Amcal to claim it as their own, has a 60% penetration of the Australian market.
In our recent Conversation Read told me that the knowledge and experience they have gained in the Australian market has led them to confidently start tackling global markets like the United States, UK and South East Asia.
Medadvisor has struck two new deals in the United States, been endorsed by a major UK pharmacy body and signed a 50/50 joint venture with a major South East Asian pharmacy chain.
[IMPORTANT: THIS ARTICLE AND INTERVIEW IS BY NO MEANS A DEFINITIVE EXPLORATION OF THE BUSINESS FEATURED AND NO INVESTMENT DECISIONS SHOULD BE MADE BASED ON THIE INFORMATION FOUND ANYWHERE ON THIS WEBSITE. PLEASE READ OUR FULL DISCLAIMER BEFORE MAKING ANY INVESTMENT DECISIONS ABOUT ANY COMPANIES MENTIONED ON THIS WEBSITE AND SEEK THE ADVICE OF A PROFESSIONAL ADVISOR.]
Useful navigation links.
WHAT MEDADVISOR DOES l SHARE PRICE TREND OVER 200/100/9 DAYS l ANALYSTS VIEWS l TECH AND COMMERCIAL READINESS INDEX
ABOUT MEDADVISOR:
MedAdvisor Limited [ASX:MDR] is an Australian software systems developer focused on addressing gaps in personal medication adherence. MedAdvisor's free app connects to pharmacy dispensing systems to automatically retrieve medication records and drive an intelligent training, information and reminder system to ensure correct and reliable medication use. MedAdvisor delivers a connected health system that empowers patients. MedAdvisor's free app connects to pharmacy dispensing systems to automatically retrieve medication records and drive an intelligent training, information and reminder system to ensure correct and reliable medication use.
TECHNOLOGY AND COMMERCIAL READINESS.
Based on the Technology Readiness Level [TRL] developed by NASA and the Commercial Readiness Index [CRI] that grew out of it. MEDADVISOR would fit somewhere around 3 to 4 on the Commercial Readiness Index.
SOME OF THE RECENT MARKET ANNOUNCEMENTS BY MEDADVISOR:
Quarterly Activities Report June 2020
MedAdvisor strikes strategic alliance with NASDAQ-listed HMS to accelerate US growth.
SOME RATINGS FOR MEDADISOR [ASX:MDR]
[CURRENT ON TUESDAY 4TH AUGUST 2020]
Morningstar Quantitative [algorithmic] Rating *
Valuation Rating: Undervalued I Fair Value Estimate 0.525
Fair Value Percentage Diff:10.53% I Liquidity: I Medium.
DISCLOSURE
The author does not own shares in this company at the time of writing this post. Inside Market does not accept any payment from this or any other company we cover. Inside Market charges a licensing fee for the re-publication of any content on this site. Any information in this article or anywhere on the InsideMarket site should be considered in any way, a recommendation to invest in this or any other company covered here. Nor should it be seen as a form of financial or investment advice. Disruptive technology stocks should be considered very speculative, high-risk, and extremely volatile. There are significant risks inherent in developing new technologies that are not discussed here. You should always seek professional advice before considering any share purchase or sale. Please read our full disclaimer. Insidemarket.net is intended for general news and information purposes only. Nothing in Insidemarket.net constitutes or is intended to constitute investment, financial, property, business, marketing, accounting, mortgage or legal advice and should not be relied upon by any person as a substitute for professional advice. Readers are strongly encouraged to seek independent legal, financial or other relevant or applicable advice before making any related decision. READ FULL DISCLAIMER HERE
* The Morningstar rating uses a machine-learning model to rate 22 times more funds than are rated by Morningstar analysts in EMEA and Asia.
The Quantitative Rating is an extension of the recently enhanced Morningstar Analyst RatingTM for funds (Analyst Rating), which provides an analyst's forward-looking assessment of a fund's ability to outperform its peer group or a relevant benchmark on a risk-adjusted basis over a full market cycle. Morningstar EMEA and Asia manager research analysts assign Analyst Ratings to approximately 1,260 open-end and exchange-traded funds and together with the Quantitative Rating, cover approximately 29,200 funds, representing nearly 105,000 share classes in EMEA and Asia.